1522.1 – PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma

New MBS item.

Immunohistochemistry (IHC) test for evaluation of Programmed Cell Death-Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. The biopsy sample taken as part of a standard diagnostic process will be used for immunohistochemical testing with PD-L1. The testing would be done by a pathologist alongside other immunohistochemical tests which are done routinely.

Type: PBAC co-dependent technology

Recurrent or metastatic head and neck squamous cell carcinoma. Head and neck cancer includes tumours arising from the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid and salivary glands. Individuals who have progressed following initial definitive treatment have recurrent disease and require subsequent treatment. Patient who present with metastatic disease generally receive the same therapy as those with recurrent disease following initial definitive treatment.

• PASC meeting: -
• ESC meeting: 7 to 8 October 2021
• MSAC meeting: 25 to 26 November 2021